Cara Therapeutics
Mar 9, 2017

Cara Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results

- Conference call today at 4:30 p.m. ET -

STAMFORD, Conn., March 09, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (NASDAQ:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2016.

"In 2016, we advanced our three late-stage trials in indications of high unmet need where existing therapies are ineffective or are limited by significant side effects and the high potential for abuse," said Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "We look forward to a transformative 2017, as we anticipate sharing efficacy data for CR845 in uremic pruritus, acute postoperative pain and chronic pain."  

Fourth Quarter and Recent Business Highlights

Expected 2017 Milestones

Fourth Quarter 2016 Financial Results

Net Loss: The Company reported a net loss of $22.0 million, or $0.81 per basic and diluted share, for the fourth quarter of 2016 compared to a net loss of $9.5 million, or $0.35 per basic and diluted share, for the same period of 2015.

Revenues: The Company did not recognize any revenues during the fourth quarter of 2016 or 2015.

Research and Development (R&D) Expenses: R&D expenses were $20.3 million in the fourth quarter of 2016 compared to $7.6 million in the same period of 2015. The higher R&D expenses in the fourth quarter of 2016 were principally due to a net increase in direct clinical trial costs and an increase in payroll and related costs for R&D personnel.

General and Administrative (G&A) Expenses: G&A expenses were $2.0 million in the fourth quarter of 2016 compared to $2.2 million in the same period of 2015. The decrease in the fourth quarter of 2016 was primarily due to a decrease in franchise tax and amortization expense, which were partially offset by increases in payroll and related costs.

Full Year 2016 Financial Results

Net Loss: The Company reported a net loss of $57.3 million, or $2.10 per basic and diluted share, for 2016 compared to a net loss of $24.7 million, or $1.00 per basic and diluted share, for 2015.

Revenues: License and milestone fees revenue was $1.7 million for 2015 (representing $1.1 million of the $1.7 million milestone payment earned in September 2015 under the Maruishi Agreement, which was attributable to the previously delivered license, and $600,000 from the two milestone payments earned by the Company under the CKD Agreement in July and September 2015). No license and milestone fees revenue was recognized in 2016.

Collaborative revenue was $2.1 million for 2015 (consisting of $600,000 of the $1.7 million milestone payment earned in September 2015 under the Maruishi Agreement, which was attributable to the fully delivered R&D services deliverable, and $1.5 million of revenue that had been deferred upon entry into the Maruishi Agreement). No collaborative revenue was recognized in 2016.

Clinical compound revenue for 2016 and 2015 was $86,000 and $0, respectively, from the sale of clinical compound to Maruishi.

Research and Development (R&D) Expenses: R&D expenses were $49.3 million in 2016 compared to $21.2 million in 2015. The higher R&D expenses in 2016 were principally due to a net increase in direct clinical trial costs, consultant services in support of clinical trials, and increases in payroll and related costs for R&D personnel and in rent.

General and Administrative (G&A) Expenses: G&A expenses were $9.2 million in 2016 compared to $7.8 million in 2015. The increase in 2016 was primarily due to increases in payroll and related costs, rent, amortization, public/investor relations costs, insurance costs and professional fees, including accounting and audit fees.

Other Income: Other income was $652,000 in 2016 compared to $101,000 in 2015. The increase in 2016 was primarily due to (1) an increase in interest income and dividends earned on our portfolio of investments, which included marketable securities during the entire year ended December 31, 2016 but only during the last month of the year ended December 31, 2015 and (2) higher interest rates and a higher average balance of cash and cash equivalents and marketable securities in 2016 as a result of our follow-on offering of common stock, which closed in August 2015.

Cash and Cash Equivalents and Marketable Securities Position: At December 31, 2016, cash and cash equivalents and marketable securities totaled $58.3 million compared to $106.7 million at December 31, 2015. The decrease in the balance of cash and cash equivalents and marketable securities primarily resulted from cash used in operations of $47.4 million.

Financial Guidance

Based on timing expectations and projected costs for current clinical development plans, Cara expects that its existing cash and cash equivalents and available-for-sale marketable securities as of December 31, 2016 will be sufficient for the Company to fund its operating expenses and capital expenditure requirements through the end of the first quarter of 2018, without giving effect to any potential milestone payments under existing collaborations. 

Conference Call

Cara management will host a conference call today at 4:30 p.m. ET to discuss fourth quarter and full year 2016 financial results and provide a business update.

To participate in the conference call, please dial 855-445-2816 (domestic) or 484-756-4300 (international) and refer to conference ID 70053458. A live webcast of the call can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com.

An archived webcast recording will be available on the Cara website beginning approximately two hours after the call.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Forward-looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements include statements concerning the expected timing of the Company's planned clinical trials, the potential results of ongoing and planned clinical trials, future regulatory and development milestones for the Company's product candidates and the Company's expected cash reach. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Cara Therapeutics' filings with the Securities and Exchange Commission, including the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2016 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cara Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Financial tables follow

CARA THERAPEUTICS, INC. 
STATEMENTS OF OPERATIONS 
(amounts in thousands, except share and per share data) 
(unaudited) 
           
   Three Months Ended
December 31,
 Year Ended December 31, 
    2016   2015   2016   2015  
                   
Revenue:         
 License and milestone fees $-  $-  $-  $1,710  
 Collaborative revenue  -   -   -   2,093  
 Clinical compound revenue  -   -   86   -  
Total revenue  -   -   86   3,803  
           
Operating expenses:         
 Research and development  20,277   7,568   49,253   21,221  
 General and administrative  2,038   2,161   9,233   7,770  
Total operating expenses  22,315   9,729   58,486   28,991  
Operating loss  (22,315)  (9,729)  (58,400)  (25,188) 
           
Other income  155   52   652   101  
Loss before benefit from income taxes  (22,160)  (9,677)  (57,748)  (25,087) 
           
Benefit from income taxes  189   147   468   397  
Net loss $(21,971) $(9,530) $(57,280) $(24,690) 
            
Net loss per share :         
Basic and Diluted $(0.81) $(0.35) $(2.10) $(1.00) 
           
Weighted average shares:         
Basic and Diluted  27,290,548   27,240,369   27,279,008   24,620,372  
           

 

CARA THERAPEUTICS, INC.
BALANCE SHEETS
(in thousands)
(unaudited)
      
   December 31,
    2016   2015 
          
Assets    
Current assets:    
 Cash and cash equivalents $12,092  $15,101 
 Marketable securities  46,184   91,640 
 Income tax receivable  852   384 
 Other receivables  87   80 
 Prepaid expenses  1,530   1,729 
 Restricted cash, current  700   -  
Total current assets  61,445   108,934 
Property and equipment, net  1,614   1,263 
Restricted cash   769   700 
Total assets $63,828  $110,897 
      
Liabilities and stockholders' equity    
Current liabilities:    
  Accounts payable and accrued expenses $11,533  $5,268 
Total current liabilities  11,533   5,268 
      
Deferred lease obligation  1,570    585 
      
Commitments and contingencies    
      
Stockholders' equity:    
 Preferred stock  -   - 
 Common stock  27   27 
 Additional paid-in capital  212,866   209,943 
 Accumulated deficit  (162,171)  (104,891)
 Accumulated other comprehensive income  (loss)  3   (35)
Total stockholders' equity  50,725    105,044 
Total liabilities and stockholders' equity $63,828  $110,897 
      


INVESTOR CONTACT:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com



MEDIA CONTACT:

Annie Starr

6 Degrees

973-415-8838

astarr@6degreespr.com

Primary Logo

Source: Cara Therapeutics Inc.

News Provided by Acquire Media